{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:34:51Z","timestamp":1790634891414,"version":"4.1.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T00:00:00Z","timestamp":1727222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>There have been conflicting reports on the predictive impact of metastatic disease sites on the response to checkpoint inhibitors (CPI) in microsatellite instability (MSI) metastatic colorectal cancers (mCRC). Recent studies have highlighted peritoneal metastases, ascites, and liver metastases as possible indicators of resistance to CPI.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We performed a detailed analysis of high microsatellite instability (MSI-H) mCRC treated with programmed cell death (PD-1) or PD-1\/cytotoxic T-lymphocyte-associated protein 4 CPI in a single center. Overall response rate (ORR), progression-free survival (PFS), overall survival (OS), and stable disease but with complete pathological response upon resection (SDcPR) were analyzed by the presence of liver metastases, peritoneal metastases, or absence of either. The impact of number and size of liver metastases on clinical outcomes were also interrogated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Thirty-five patients with MSI mCRC were included in the analysis. Patients with peritoneal metastatic disease had lower ORR and shorter PFS compared to patients without liver and peritoneal metastases. Contrary to recent reports, ORR and ORR\u2005+\u2005SDcPR rates were high in patients with liver metastases, at 58% and 66%, respectively. In the liver metastases category, a better response rate was noted for patients with&amp;lt;5 lesions compared to patients with more than 5 lesions. Patients who responded had a higher median tumor mutation burden than patients with progressive disease.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In MSI mCRC, no single clinical characteristic was sufficient to preclude CPI response. Peritoneal metastatic disease was associated with numerically lower ORR and shorter PFS. In contrast, liver metastases do not predict poor outcome.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyae249","type":"journal-article","created":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T19:22:36Z","timestamp":1727292156000},"page":"1052-1058","source":"Crossref","is-referenced-by-count":8,"title":["Liver metastases and peritoneal metastases and response to checkpoint inhibitors in metastatic colorectal cancer with microsatellite instability"],"prefix":"10.1093","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6554-5488","authenticated-orcid":false,"given":"Marwan","family":"Fakih","sequence":"first","affiliation":[{"name":"Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center , Duarte, CA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaideep","family":"Sandhu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center , Duarte, CA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochen","family":"Li","sequence":"additional","affiliation":[{"name":"Division of Biostatistics, Department of Computational and Quantitative Medicine, City of Hope Comprehensive Cancer Center , Duarte, CA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2186-8875","authenticated-orcid":false,"given":"Chongkai","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center , Duarte, CA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,9,25]]},"reference":[{"issue":"7407","key":"2024121021051206800_CIT0001","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nature11252","article-title":"Comprehensive molecular characterization of human colon and rectal cancer","volume":"487","author":"Muzny","year":"2012","journal-title":"Nature"},{"issue":"6","key":"2024121021051206800_CIT0002","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1053\/j.gastro.2009.12.064","article-title":"Microsatellite instability in colorectal cancer","volume":"138","author":"Boland","year":"2010","journal-title":"Gastroenterology"},{"issue":"20","key":"2024121021051206800_CIT0003","doi-asserted-by":"publisher","first-page":"5322","DOI":"10.1158\/1078-0432.CCR-14-0332","article-title":"Mismatch repair status and braf mutation status in metastatic colorectal cancer patients: a pooled analysis of the cairo, cairo2, coin, and focus studies","volume":"20","author":"Venderbosch","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2024121021051206800_CIT0004","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/2159-8290.CD-14-0863","article-title":"The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints","volume":"5","author":"Llosa","year":"2015","journal-title":"Cancer Discov"},{"issue":"1","key":"2024121021051206800_CIT0005","first-page":"148","article-title":"Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences","volume":"145","author":"Kim","year":"1994","journal-title":"Am J Pathol"},{"issue":"26","key":"2024121021051206800_CIT0006","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"Pd-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"2024121021051206800_CIT0007","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (checkmate 142): an open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol"},{"issue":"1","key":"2024121021051206800_CIT0008","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1200\/JCO.19.02107","article-title":"Phase ii open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: Keynote-164","volume":"38","author":"Le","year":"2020","journal-title":"J Clin Oncol"},{"issue":"8","key":"2024121021051206800_CIT0009","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","article-title":"Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer","volume":"36","author":"Overman","year":"2018","journal-title":"J Clin Oncol"},{"issue":"10","key":"2024121021051206800_CIT0010","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.annonc.2022.06.008","article-title":"Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from checkmate 142","volume":"33","author":"Andr\u00e9","year":"2022","journal-title":"Ann Oncol"},{"issue":"23","key":"2024121021051206800_CIT0011","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/nejmoa2017699","article-title":"Pembrolizumab in microsatellite-instability\u2013high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"2024121021051206800_CIT0012","doi-asserted-by":"publisher","first-page":"e2118416","DOI":"10.1001\/jamanetworkopen.2021.18416","article-title":"Clinical response to immunotherapy targeting programmed cell death receptor 1\/programmed cell death ligand 1 in patients with treatment-resistant microsatellite stable colorectal cancer with and without liver metastases","volume":"4","author":"Wang","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"4_suppl","key":"2024121021051206800_CIT0013","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1200\/jco.2023.41.4_suppl.187","article-title":"Comparative analysis of tumor immune microenvironment in primary tumors vs metastatic tissue in microsatellite stable metastatic colorectal cancer","volume":"41","author":"Fakih","year":"2023","journal-title":"J Clin Oncol"},{"issue":"7_Supplement","key":"2024121021051206800_CIT0014","doi-asserted-by":"publisher","first-page":"6676","DOI":"10.1158\/1538-7445.am2023-6676","article-title":"Abstract 6676: Exploratory biomarker analyses in phase 1 study of regorafenib, ipilimumab, and nivolumab (rin) in chemotherapy resistant microsatellite stable (mss) metastatic colorectal cancer (mcrc)","volume":"83","author":"Ye","year":"2023","journal-title":"Cancer Res"},{"issue":"2","key":"2024121021051206800_CIT0015","doi-asserted-by":"publisher","first-page":"e230400","DOI":"10.1001\/jamanetworkopen.2023.0400","article-title":"Association between survival and metastatic site in mismatch repair\u2013deficient metastatic colorectal cancer treated with first-line pembrolizumab","volume":"6","author":"Saberzadeh-Ardestani","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"044","key":"2024121021051206800_CIT0016","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ejca.2022.05.044","article-title":"Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dmmr\/msi-h metastatic colorectal cancer","volume":"172","author":"Mazzoli","year":"2022","journal-title":"Eur J Cancer"},{"issue":"2","key":"2024121021051206800_CIT0017","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised recist guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"1","key":"2024121021051206800_CIT0018","doi-asserted-by":"publisher","first-page":"S178","DOI":"10.1016\/j.annonc.2023.04.014","article-title":"Lba-4 results from an expanded phase 1 trial of botensilimab (BOT), a multifunctional anti-CTLA-4, plus balstilimab (BAL; anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC)","volume":"34","author":"Bullock","year":"2023","journal-title":"Ann Oncol"},{"issue":"1","key":"2024121021051206800_CIT0019","doi-asserted-by":"publisher","first-page":"S179","DOI":"10.1016\/j.annonc.2023.04.015","article-title":"LBA-5 lenvatinib plus pembrolizumab versus standard of care for previously treated metastatic colorectal cancer (MCRC): The phase 3 leap-017 study","volume":"34","author":"Kawazoe","year":"2023","journal-title":"Ann Oncol"},{"issue":"7_Supplement","key":"2024121021051206800_CIT0020","doi-asserted-by":"publisher","first-page":"4406","DOI":"10.1158\/1538-7445.am2023-4406","article-title":"Abstract 4406: Impact of site of metastases on response to immunotherapy in microsatellite stable (MSS) metastatic colorectal cancer (MCRC)","volume":"83","author":"Fakih","year":"2023","journal-title":"Cancer Res"},{"issue":"10","key":"2024121021051206800_CIT0021","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1158\/2767-9764.CRC-23-0212","article-title":"Peritumoral immune-suppressive mechanisms impede intratumoral lymphocyte infiltration into colorectal cancer liver versus lung metastases","volume":"3","author":"Ye","year":"2023","journal-title":"Cancer Res Commun"},{"issue":"1","key":"2024121021051206800_CIT0022","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/cjp2.178","article-title":"Prognostic assessment of resected colorectal liver metastases integrating pathological features, ras mutation and immunoscore","volume":"7","author":"Baldin","year":"2021","journal-title":"J Pathol Clin Res"},{"issue":"1","key":"2024121021051206800_CIT0023","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1093\/jnci\/djx123","article-title":"Comprehensive intrametastatic immune quantification and major impact of immunoscore on survival","volume":"110","author":"Mlecnik","year":"2018","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"2024121021051206800_CIT0024","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1093\/annonc\/mdz134","article-title":"Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer","volume":"30","author":"Schrock","year":"2019","journal-title":"Ann Oncol"},{"issue":"5","key":"2024121021051206800_CIT0025","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S1470-2045(22)00197-8","article-title":"Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (keynote-177): final analysis of a randomised, open-label, phase 3 study","volume":"23","author":"Diaz","year":"2022","journal-title":"Lancet Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/12\/1052\/60952540\/oyae249.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/12\/1052\/60952540\/oyae249.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T21:48:46Z","timestamp":1733867326000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/29\/12\/1052\/7775405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,25]]},"references-count":25,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,9,25]]},"published-print":{"date-parts":[[2024,12,6]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyae249","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,9,25]]}}}